Otsuka/Lundbeck’s Rexulti Has Time To Build A Lead In The Alzheimer’s Agitation Market

 
• By Alaric DeArment
  
Otsuka/Lundbeck received approval for Rexulti in AAD • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip